Washington, D.C. — The Food and Drug Administration has announced that it will conduct a review of Moderna’s application for a novel mRNA flu vaccine. This decision comes after the company agreed to enhance its study involving older adults—a critical demographic for flu vaccination.
Initially, the FDA startled the biotech industry by refusing to review Moderna’s application, citing a lack of comparative data against a high-dose flu vaccine targeted at older populations. This decision spurred concerns regarding the regulatory landscape as the agency has faced scrutiny for perceived inconsistency in its processes. However, the FDA has since charted a new course, indicating that it will proceed with the review, albeit with modifications.
During a recent industry event, FDA Commissioner Marty Makary suggested that the agency’s earlier refusal was part of an ongoing dialogue with Moderna. He highlighted the importance of discussions between regulators and companies, suggesting that such interactions can lead to productive outcomes.
Despite the reversal, some experts remain skeptical. Rena Conti, a health economist at Boston University, has criticized what she perceives as erratic decision-making within the agency. “This approach can create uncertainty in the industry, making it difficult to plan for the future,” Conti said.
Moderna has leveraged its mRNA technology to develop the COVID-19 vaccine quickly, and the company aspires to accomplish the same for its flu vaccine. With an investment exceeding $1 billion—partly funded by Blackstone, a major asset management firm—Moderna aims to introduce a new vaccination option to combat seasonal flu.
The FDA’s initial reluctance stemmed from the absence of a rigorous clinical trial comparing Moderna’s vaccine with an existing, CDC-recommended flu vaccine. However, Moderna argued that it had received the FDA’s approval for its study design 18 months earlier. The company emphasized that it had submitted additional data from a separate trial to the FDA, demonstrating the mRNA vaccine’s effectiveness against a high-dose counterpart.
Health and Human Services Department spokesman Andrew Nixon clarified that the agency’s rejection was based on Moderna’s failure to comply with specific FDA guidelines regarding clinical trials. Following a recent meeting, Moderna amended its application, which the FDA has now accepted for review.
In addition, Moderna has committed to conducting a confirmatory study involving a high-dose flu vaccine after its mRNA version receives market approval. The company asserts that it expects the vaccine could be available for the upcoming flu season, contingent on regulatory approval.
As the landscape of vaccine development continues to evolve, the FDA’s decisions will likely have lasting implications for both industry stakeholders and public health initiatives aimed at reducing the impact of seasonal influenza.